Saltar al contenido

Lilly Registers Two Phase 3 Trials of EloraTZP, Its Eloralintide-Tirzepatide Combination

27 de octubre de 2026 · 6 min

Notas del episodio

Eli Lilly has registered two phase 3 trials of EloraTZP, an investigational once-weekly combination of the amylin agonist eloralintide and tirzepatide (the active ingredient in Zepbound and Mounjaro), on ClinicalTrials.gov. We walk through how the trials are set up: AMPLIFY-1 plans to enroll about 2,115 adults with obesity and without diabetes and compares several EloraTZP doses with tirzepatide alone, eloralintide alone and placebo; AMPLIFY-2 plans to enroll about 1,000 adults with obesity or overweight and type 2 diabetes and compares EloraTZP with tirzepatide alone. Both trials measure percent change in body weight at week 100, were first posted on October 19, 2026, are not yet recruiting, and are estimated to finish in late 2029. We also recap the September 2026 phase 2b results that Lilly says led to the move (367 adults with type 2 diabetes over 48 weeks), including weight loss, A1C changes and treatment discontinuations due to side effects, and why those figures come with caveats. EloraTZP and eloralintide are investigational drugs that are not approved. Sources: - ClinicalTrials.gov, AMPLIFY-1 (NCT07881432), "A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes" (first posted Oct 19, 2026): https://clinicaltrials.gov/study/NCT07881432 - ClinicalTrials.gov, AMPLIFY-2 (NCT07881458), "A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes" (first posted Oct 19, 2026): https://clinicaltrials.gov/study/NCT07881458 - Eli Lilly news release, EloraTZP phase 2b results (Sept 30, 2026): https://investor.lilly.com/news-releases/news-release-details/lillys-eloratzp-combination-eloralintide-and-tirzepatide - Reuters via KSL.com, "Experimental Lilly combination drug tops Zepbound in weight-loss trial" (Sept 30, 2026): https://www.ksl.com/article/51630539/experimental-lilly-combination-drug-tops-zepbound-in--weight-loss-trial - CHOSUNBIZ, "Lilly advances amylin-based obesity combo to phase 3, tests tolerability amid Korea race" (Oct 26, 2026): https://biz.chosun.com/en/en-science/2026/10/26/VTWAF3F4D5DYTCZDOHBMIUET3A/ Cover: original abstract illustration made for this episode (two merging droplets); no photo used. This show is for information only and is not medical advice. Always talk to your doctor before starting, stopping, or changing any medication. Visit glp1newspaper.com to see today's stories and sign up for free email alerts.

Todos los episodios de GLP-1 Newspaper: Daily Ozempic, Zepbound & Weight-Loss Drug News

Ajustes

Visualización

Idioma

Determina qué emisoras ves primero en la página de inicio.

Historial

Las emisoras y episodios escuchados recientemente y tus últimas búsquedas solo se guardan en este navegador.

Avisos

Un breve aviso cuando un pódcast que sigues tiene un episodio nuevo. Puedes desactivar pódcast concretos con la campana de su página.

Cuenta

Guarda tus favoritos: en la app y en la web.

Atajos de teclado

/
Abrir búsqueda
Espacio
Reproducir o pausar
← →
En el reproductor: 15 s atrás, 30 s adelante (episodios) · en una fila: siguiente tarjeta
↑ ↓
En una fila: destino dentro de la tarjeta
Inicio / Fin
En una fila: primera o última tarjeta
Esc
Cerrar ventana o menú
?
Este resumen
Reproduciendo ahora

Ir a la emisora

A continuación

    Añade episodios con «A continuación»: sonarán después del episodio actual.